




Patent Application
Attorney Docket No. PC11812-AKM

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, Washington, D.C. 20231 on this 3rd day of June, 2002.

By


(Signature of person mailing)

Erica L. Smith

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Robert L. Dow, et al. :

APPLICATION NO.: 10/086,588 : Examiner:

FILING DATE: February 28, 2002 : Group Art Unit: 1614

TITLE: Beta 3 Agonists and Uses Thereof :

Hon. Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.


Pursuant to 37 C.F.R. 1.97(b)(3); and 1.98, Applicant's agent wishes to draw the Examiner's attention to PTO-FB-A820 which lists the reference cited by the applicant, a copy of which is enclosed.

The Examiner is respectfully requested to indicate his or her consideration of the foregoing item by initialing, signing, and dating the accompanying PTO-FB-A820 and then returning a copy of the same to the undersigned. This information disclosure statement is being submitted prior to receiving a first office action; therefore, no fee is required. In the event that an office action has been mailed, please charge the appropriate fee to Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: June 3, 2002
Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-0871


Arlene K. Musser
Attorney for Applicant(s)
Reg. No. 37,895

RECEIVED
JUN 11 2002

TECH CENTER 1600/2900

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. PC11812AAKM

SERIAL NO. 10/086,588

APPLICANT Robert L. Dow, et al.

FILING DATE February 28, 2002

GROUP 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING D IF APPROP
	5 9 7 7 1 2 4	11/2/99	Dow	514	272	
	5 7 7 6 9 8 3	7/7/98	Washburn, et al.	514	605	
	5 0 3 0 6 4 0	7/9/91	Fisher, et al.	514	339	
	5 0 1 9 5 7 8	5/28/91	Fisher, et al.	514	275	
	4 4 7 8 8 4 9	10/23/84	Ainsworth, et al.	424	285	
	4 3 5 8 4 5 5	11/9/82	Atkinson, et al.	424	263	
	5 1 5 3 2 1 0	10/6/92	Ainsworth, et al.	514	369	
	5 7 0 5 5 1 5	1/6/98	Fisher, et al.	514	365	
	5 7 9 2 8 7 1	8/11/98	Chartrain, et al.	546	335	

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA	
													YES	
	EP	0	5	1	6	3	4	9	12/2/92	European	C07C	217/18		
	WO	9	9	6	5	8	7	7	12/23/99	International	C07D	213/80		
	WO	0	2	0	6	2	7	4	1/24/02	International	C07D	401/12		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

			Tesfamariam, B. et al., "β1 – and β2-Adrenoceptor Antagonist Activities of ICI-215001, a Putative β3-Adrenoceptor Agonist", 1 55-58 (1994).
			Martin, et al., "Effects of Two β3-Adrenoceptor Agonists, SR 58611A and BRL 37344, and of Salbutamol on Cholinergic and NAN Neural Contraction in Guinea-pig Main Bronchi <i>in vitro</i> ", 110, 1311-1316 (1993).
			Giudice, et al., "Inhibition of Rat Colonic Motility and Cardiovascular Effects of New Gut-Specific Beta-Adrenergic Phenylethanolaminotetralines", 44, 1411-1417 1989).
			Simiand, et al., "Antidepressant Profile In Rodents of SR 58611A, a New Selective Agonist for Atypical β-adrenoceptors", 219, 19 201 1992.
			Taneja, et al., "Evidence for a Noradrenergic Innervation to « Atypical » Beta Adrenoceptors (or Putative Beta-3 Adrenoceptors) the Ileum of Guinea Pig", 260, 192-200 (1992).
			Krief, et al., "Tissue Distribution of β3-adrenergic Receptor mRNA in Man", 91 344-349 (1993).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with